Bidstack Group PLC (LON:BIDS) was up 7% to 2.14p before close on the back of two new exclusive partnerships.

The advertising firm signed with Rebound Capital Games (RCG) for its popular mobile game Tennis Manager 2021, which will offer brands an opportunity to “engage with tennis fans across a number of tier-one markets as the tennis season progresses”.

It also inked an agreement with Belgrade-based Nordeus, best known for its flagship game Top Eleven, which boost its stadium vertical, described as “a natural environment lending itself well to native in-game advertising”.

2.55pm: Vectura on the surge after unveiling £1bn takeover by Philip Morris 

Vectura Group PLC (LON:VEC) climbed 14% to 154.3p in the afternoon after agreeing a £1bn takeover offer with Philip Morris International Inc. (NYSE:PM).

The inhaled medicines specialist withdrew its recommendation for the £958mln proposal put forward by private equity firm Carlyle Group in May.

The cigarette maker looks to add Vectura to its “beyond nicotine” portfolio which is planned to generate at least US$1bn revenues by 2025, having identified respiratory drug delivery as a key focus.

1.20pm: Arc Minerals slips after exclusivity period agreement with Anglo American lapses

Arc Minerals PLC (LON:ARCM) slipped 13% to 4.37p after the exclusivity period agreement with Anglo American (LON:AAL) lapsed.

During this period, which started in July 2020, Anglo had permission to conduct a technical review of Arc’s copper exploration licences in Zambia.

The expectation was that if the results of the review proved satisfactory it might result in an extension of the exclusivity and the negotiation of a commercial transaction.

“As we have always said, any transaction has to sufficiently compensate Arc shareholders for allowing a major to take over an asset which we believe has significant potential to become a major tier-one copper discovery. We will continue our discussions with Anglo American which have been going well but will also commence discussions with other major mining companies that have approached us,” said Arc’s chairman, Nick von Schirnding.

12.15pm: Keras Resources in demand after kicking off commercial production at Diamond Creek

Keras Resources PLC (LON:KRS) advanced 8% to 0.1p at lunchtime after announcing that commercial production has started at the phosphate mine, Diamond Creek in Utah, US.

The project is owned by Falcon Isle, in which the AIM-listed firm has a 51% holding, which is holding discussions with potential clients.

Commissioning is complete and the milling plant is now at steady-state operational capacity, with production to begin later this month.

11am: Cambridge Cognition shoots higher after winning £1mln cancer trial contract

Cambridge Cognition Holdings PLC (LON:COG) shot up by a tenth to 180.4p after winning a £1mln contract to carry out cognitive assessments at a late phase cancer trial.

The brain health solutions developer said it is the second contract for a top ten pharmaceutical company with a strong pipeline of oncology products, which will implement the AIM-listed firm’s CANTAB technology across all 150 trial sites.

Cancer survival has doubled in the last 40 years in the UK and, with patients now living longer, there is more focus on limiting potentially detrimental long-term side effects of both diagnosis and treatment.

10am: Ilika, Empyrean Energy both plunge after placing shares at discount

Ilika plc (LON:IKA) plunged 25% to 150.5p after announcing a discounted placing to raise £18mln.

Shares were placed at 140p a pop, a discount of 30% to Thursday’s closing price.

The solid-state batteries manufacturer said the cash will be used to support the development of electric vehicle pouch cells through its Goliath programme.

Similarly, Empyrean Energy PLC (LON:EME) dropped 22% to 6.6p after raising £5mln via a placing of 83mln shares.

The oil and gas development company placed shares at 6p each, also a 29.4% discount to the latest closing price.

It will use the money as preparation to drill the Jade prospect at its 100% owned Block 29/11 license in China, scheduled for late 2021.

9am: President Energy higher after subsidiary acquires Northern European green hydrogen and ammonia firm

President Energy PLC (LON:PPC) rose 7% to 2.35p after its hydrogen and ammonia production subsidiary Atome made an acquisition.

It snapped up a 75% interest in “a Northern European based green hydrogen and ammonia firm” for nominal share value.

President said the firm has no tangible assets at present but it has experienced local management with a “reputable” chief executive in the country where it is located.

Elsewhere, Open Orphan PLC (LON:ORPH) added 4% to 36p after its hVIVO subsidiary won a deal to test an antiviral in human challenge studies using the common cold and flu virus.

It will be working with Philadelphia-based AIM ImmunoTech’s drug Ampligen as part of a phase II trial, which is expected to kick off in the fourth quarter.

Open Orphan said the latest contract demonstrated the breadth of its service offering and its ability to test multiple pathogens at once in its state-of-the-art zoned unit, “reinforcing its status as the world leader in its field”.